Arena Pharmaceuticals (ARNA)

Create an Alert
7.51 +0.01  +0.13%   NASDAQ Jun 18, 5:00PM BATS Real time Currency in USD

Arena Pharmaceuticals R&D Expense Quarterly:

14.01M for March 31, 2013
View Full Chart

Arena Pharmaceuticals R&D Expense Quarterly Chart

    Arena Pharmaceuticals Historical R&D Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 2   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    March 31, 2013 14.01M
    Dec. 31, 2012 13.95M
    Sept. 30, 2012 11.62M
    June 30, 2012 14.08M
    March 31, 2012 14.47M
    Dec. 31, 2011 13.09M
    Sept. 30, 2011 14.98M
    June 30, 2011 14.70M
    March 31, 2011 15.94M
    Dec. 31, 2010 16.49M
    Sept. 30, 2010 20.16M
    June 30, 2010 20.50M
    March 31, 2010 18.31M
    Dec. 31, 2009 21.19M
    Sept. 30, 2009 22.15M
    June 30, 2009 24.20M
    March 31, 2009 42.62M
    Dec. 31, 2008 52.73M
    Sept. 30, 2008 47.67M
    June 30, 2008 56.41M
    March 31, 2008 Go Pro
    Dec. 31, 2007 Go Pro
    Sept. 30, 2007 Go Pro
    June 30, 2007 Go Pro
    March 31, 2007 Go Pro
       
    Dec. 31, 2006 Go Pro
    Sept. 30, 2006 Go Pro
    June 30, 2006 Go Pro
    March 31, 2006 Go Pro
    Dec. 31, 2005 Go Pro
    Sept. 30, 2005 Go Pro
    June 30, 2005 Go Pro
    March 31, 2005 Go Pro
    Dec. 31, 2004 Go Pro
    Sept. 30, 2004 Go Pro
    June 30, 2004 Go Pro
    March 31, 2004 Go Pro
    Dec. 31, 2003 Go Pro
    Sept. 30, 2003 Go Pro
    June 30, 2003 Go Pro
    March 31, 2003 Go Pro
    Dec. 31, 2002 Go Pro
    Sept. 30, 2002 Go Pro
    June 30, 2002 Go Pro
    March 31, 2002 Go Pro
    Dec. 31, 2001 Go Pro
    Sept. 30, 2001 Go Pro
    June 30, 2001 Go Pro
    March 31, 2001 Go Pro
    Dec. 31, 2000 Go Pro

    About R&D Expense

    R&D expenses are a line item from many companies' income statements.

    R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

    Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

    An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
    Learn More

    Get data for

    ARNA R&D Expense Quarterly Benchmarks

    Companies
    Vivus 7.046M
    Orexigen Therapeutics 28.25M
    ACADIA Pharmaceuticals 4.43M

    ARNA R&D Expense Quarterly Rankings

    Overall 96th percentile
    664 of 16773
    Sector 87th percentile
    169 of 1408 in Healthcare
    Industry 86th percentile
    60 of 453 in Biotechnology

    ARNA R&D Expense Quarterly Range, Past 5 Years

    Minimum 11.62M Sep 2012
    Maximum 56.41M Jun 2008
    Average 23.46M

    Access watchlists and custom data alerts.
    Start your free account.

    Registering enables you to view unlimited pages per month.

    required
    required
    required
    required
    Get Started Now

    Already registered? Sign in here.

    document.write('');